PE20221417A1 - Degradadores bifuncionales de brd9 y sus metodos de uso - Google Patents

Degradadores bifuncionales de brd9 y sus metodos de uso

Info

Publication number
PE20221417A1
PE20221417A1 PE2022000406A PE2022000406A PE20221417A1 PE 20221417 A1 PE20221417 A1 PE 20221417A1 PE 2022000406 A PE2022000406 A PE 2022000406A PE 2022000406 A PE2022000406 A PE 2022000406A PE 20221417 A1 PE20221417 A1 PE 20221417A1
Authority
PE
Peru
Prior art keywords
brd9
methods
degraders
bifunctional
bifunctional degraders
Prior art date
Application number
PE2022000406A
Other languages
English (en)
Inventor
Julien Lorber
Martin Sendzik
Xin Chen
Marie-Line Goude
Edmund Martin Harrington
Gregory John Hollingworth
Anna Vulpetti
Thomas Zoller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20221417A1 publication Critical patent/PE20221417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La divulgacion proporciona compuestos bifuncionales para BRD9 de Formula (A), o una de sus sales, hidratos, solvatos, profarmacos, estereoisomeros o tautomeros farmaceuticamente aceptables, su preparacion, composiciones farmaceuticas que los comprenden, y su uso en el tratamiento de enfermedades y trastornos mediados por una proteina con bromodominio, tal como proteina con bromodominio 9 (BRD9).
PE2022000406A 2019-09-16 2020-09-14 Degradadores bifuncionales de brd9 y sus metodos de uso PE20221417A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900869P 2019-09-16 2019-09-16
US201962900863P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
PCT/US2020/050768 WO2021055295A1 (en) 2019-09-16 2020-09-14 Brd9 bifunctional degraders and their methods of use

Publications (1)

Publication Number Publication Date
PE20221417A1 true PE20221417A1 (es) 2022-09-20

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000406A PE20221417A1 (es) 2019-09-16 2020-09-14 Degradadores bifuncionales de brd9 y sus metodos de uso

Country Status (19)

Country Link
US (1) US20220315578A1 (es)
EP (1) EP4041724A1 (es)
JP (1) JP2022547952A (es)
KR (1) KR20220063192A (es)
CN (1) CN114641473A (es)
AU (1) AU2020349451B2 (es)
BR (1) BR112022003514A2 (es)
CA (1) CA3153529A1 (es)
CO (1) CO2022002842A2 (es)
CR (1) CR20220105A (es)
DO (1) DOP2022000053A (es)
EC (1) ECSP22018571A (es)
IL (1) IL290677A (es)
JO (1) JOP20220069A1 (es)
MX (1) MX2022003102A (es)
PE (1) PE20221417A1 (es)
TW (1) TW202123942A (es)
UY (1) UY38880A (es)
WO (1) WO2021055295A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152440A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Methods and compounds for treating disorders
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
IL295101A (en) * 2020-01-29 2022-09-01 Foghorn Therapeutics Inc materials and their use
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023039208A1 (en) * 2021-09-09 2023-03-16 C4 Therapeutics, Inc. Selected compounds for targeted degradation of brd9
WO2023109892A1 (zh) * 2021-12-15 2023-06-22 海思科医药集团股份有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2017281903B2 (en) * 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
MX2019009046A (es) * 2017-01-31 2019-10-30 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
WO2019186343A1 (en) * 2018-03-26 2019-10-03 Novartis Ag N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
CN111936501B (zh) * 2018-03-26 2023-09-22 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
WO2020160198A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof

Also Published As

Publication number Publication date
JP2022547952A (ja) 2022-11-16
DOP2022000053A (es) 2023-01-31
TW202123942A (zh) 2021-07-01
EP4041724A1 (en) 2022-08-17
BR112022003514A2 (pt) 2022-05-17
KR20220063192A (ko) 2022-05-17
JOP20220069A1 (ar) 2023-01-30
AU2020349451B2 (en) 2024-02-01
US20220315578A1 (en) 2022-10-06
WO2021055295A1 (en) 2021-03-25
IL290677A (en) 2022-04-01
CA3153529A1 (en) 2021-03-25
UY38880A (es) 2021-04-30
CO2022002842A2 (es) 2022-04-19
AU2020349451A1 (en) 2022-04-21
MX2022003102A (es) 2022-04-06
CN114641473A (zh) 2022-06-17
ECSP22018571A (es) 2022-04-29
CR20220105A (es) 2022-06-13

Similar Documents

Publication Publication Date Title
PE20221417A1 (es) Degradadores bifuncionales de brd9 y sus metodos de uso
PE20200335A1 (es) Compuestos que inhiben la proteina mcl-1
CL2022001111A1 (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
CR20160527A (es) Derivados de carboxamida
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
CL2017001602A1 (es) Derivados de fumagilol.
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR119967A1 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
CU20160170A7 (es) Derivados de carboxamida
CR9817A (es) Compuestos terapeuticos